PDFCX Performance — PGIM Target Date 2030 Fund, Class R1
Data updated: 2026-10-13
PDFCX returned +6.60% year to date and +12.56% over one year to Jul 2026. Annualised returns are +10.02% over 3 years and +5.20% over 5 years. The fund trailed its Target-Date category average: $100 invested three years ago grew to $133, against $146 for the category, and to $113 over one year, against $116. Volatility over the past three years was 7.57% a year. In the 12 months to Jul 2026 the fund lost a net $6.5M, and assets reached $54.88M.
PDFCX Growth of $100
What $100 invested in PGIM Target Date 2030 Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Target-Date category average over the same months.
| Period | PDFCX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $113 | $116 |
| 3 years (Aug 2023 – Jul 2026) | $133 | $146 |
| 5 years (Aug 2021 – Jul 2026) | $129 | $142 |
| Since data start (Aug 2019 – Jul 2026) | $164 | $186 |
PDFCX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +6.60% |
| 1 year | +12.56% |
| 3 years (annualised) | +10.02% |
| 5 years (annualised) | +5.20% |
PDFCX Annual Returns
Calendar-year total returns of PGIM Target Date 2030 Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +6.60% |
| 2025 | +11.85% |
| 2024 | +8.69% |
| 2023 | +11.79% |
| 2022 | −13.73% |
| 2021 | +14.01% |
| 2020 | +9.12% |
| 2019 (Aug–Dec) | +5.77% |
PDFCX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.0% | +1.7% | −3.6% | +5.1% | +1.7% | −0.2% | 0.0% | — | — | — | — | — |
| 2025 | +1.9% | +0.8% | −1.6% | 0.0% | +2.1% | +2.5% | +0.1% | +2.2% | +1.7% | +0.9% | +0.8% | −0.1% |
| 2024 | +0.1% | +1.5% | +2.1% | −2.8% | +3.0% | +1.0% | +1.8% | +1.8% | +1.8% | −2.1% | +2.5% | −2.2% |
| 2023 | +4.8% | −2.6% | +1.9% | +0.7% | −1.4% | +3.2% | +2.0% | −1.5% | −3.1% | −2.0% | +5.8% | +4.0% |
| 2022 | −3.0% | −1.0% | +0.9% | −5.1% | 0.0% | −6.2% | +5.8% | −3.3% | −7.7% | +3.9% | +5.2% | −3.0% |
| 2021 | −0.1% | +1.5% | +1.9% | +3.3% | +1.2% | +0.8% | +1.6% | +1.1% | −2.6% | +3.3% | −1.4% | +2.8% |
| 2020 | −0.3% | −4.8% | −10.8% | +7.2% | +3.4% | +2.1% | +3.4% | +3.3% | −2.3% | −1.5% | +7.2% | +3.1% |
| 2019 | — | — | — | — | — | — | — | −0.6% | +1.1% | +1.7% | +1.6% | +1.9% |
PDFCX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 7.57%
- 3-year Sharpe ratio: 0.73 (vs 4.5% risk-free rate)
- Best month: +5.78% (Nov 2023)
- Worst month: −3.63% (Mar 2026)
PDFCX Fund Flows
Monthly money in and out of PGIM Target Date 2030 Fund, from SEC Form N-PORT.
- 12-month net flow: −$6.5M
- 12-month gross sales (incl. reinvestments): $13.4M
- Sales ÷ redemptions: 0.67×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $534K | $725K | −$191K |
| Jun 2026 | $962K | $724K | $238K |
| May 2026 | $173K | $6.0M | −$5.8M |
| Apr 2026 | $391K | $1.2M | −$829K |
| Mar 2026 | $1.2M | $4.1M | −$2.9M |
| Feb 2026 | $268K | $579K | −$310K |
| Jan 2026 | $1.8M | $1.8M | −$43K |
| Dec 2025 | $5.1M | $459K | $4.7M |
| Nov 2025 | $1.6M | $1.2M | $317K |
| Oct 2025 | $538K | $1.2M | −$699K |
| Sep 2025 | $553K | $1.0M | −$463K |
| Aug 2025 | $275K | $777K | −$503K |
PDFCX Assets Under Management
Net assets of PGIM Target Date 2030 Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $54.88M |
| 2026-04-30 | $59.77M |
| 2026-01-30 | $62.00M |
| 2025-10-31 | $57.88M |
| 2025-07-31 | $56.71M |
| 2025-04-30 | $55.17M |
| 2025-01-31 | $58.68M |
| 2024-10-31 | $56.55M |
| 2024-07-31 | $54.31M |
| 2024-04-30 | $53.65M |
| 2024-01-31 | $54.33M |
| 2023-10-31 | $61.37M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.